<?xml version="1.0" encoding="UTF-8"?>
<p>This study was a prospective group design. The study population consisted of 30 consecutive HF outpatients with a LVEF ≤ 40% at optimal medical treatment at the time of inclusion, who were referred to the Cardiology clinic of the Medical School of the University of Mashhad, Iran, during the year 2016, in order to receive stem cell therapy in addition to the conventional treatments. The decision for stem cell therapy was made according to the patients' will in addition to their physicians' decision. Also, 30 patients with HF and (LVEF) ≤ 40% who were referred to the same clinic at the same time for receiving conventional treatments according to guideline-directed medical therapy (GDMT) were recruited by convenience sampling. All the patients were on full tolerable medical treatments for over three months which include Lisinopril 5 bid, Varvedilol 12.5 bid, Lasix 40 bid and Aldactone 25 qd at least. All drugs used in our study were made in Dr. Abidi Pharmaceutical Laboratory in Iran. Patients enrolled in the study were over 18 years of age, at least three months away from the initial diagnosis of the disease, having the ability to communicate and complete the questionnaire besides having consented to participation in the trial. Patients were excluded from the study if their serum creatinine level was &gt;2.5mg/dl, increased liver enzymes to over three times the average level, the presence of life-threatening arrhythmias and congenital cardiac disease and history of a known psychiatric disorder or psychiatric/psychological treatment.</p>
